-
Frequency Therapeutics Stock Craters After FX-322's Four Weekly Regime Shows No Benefit In Sensorineural Hearing Loss
Tuesday, March 23, 2021 - 7:54am | 441Read More...Frequency Therapeutics Inc (NASDAQ: FREQ) stock plunges in the premarket after reporting topline day-90 data from its Phase 2a study (FX-322-202) evaluating the company's lead product candidate FX-322 in sensorineural hearing loss (SNHL). What Happened: Final results...
-
Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies
Wednesday, February 24, 2021 - 2:52pm | 256Read More...Decibel Therapeutics Inc (NASDAQ: DBTX) presented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene. Decibel presented the data at the Annual MidWinter Meeting of the Association for Research in Otolaryngology. DB-OTO...
